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Abstract
Background: With the globalization of clinical trials, a growing emphasis has been placed on the standardization of the
workflow in order to ensure the reproducibility and reliability of the overall trial. Despite the importance of workflow
evaluation, to our knowledge no previous studies have attempted to adapt existing modeling languages to standardize the
representation of clinical trials. Unified Modeling Language (UML) is a computational language that can be used to model
operational workflow, and a UML profile can be developed to standardize UML models within a given domain. This paper’s
objective is to develop a UML profile to extend the UML Activity Diagram schema into the clinical trials domain, defining a
standard representation for clinical trial workflow diagrams in UML.
Methods: Two Brazilian clinical trial sites in rheumatology and oncology were examined to model their workflow and collect
time-motion data. UML modeling was conducted in Eclipse, and a UML profile was developed to incorporate information
used in discrete event simulation software.
Results: Ethnographic observation revealed bottlenecks in workflow: these included tasks requiring full commitment of
CRCs, transferring notes from paper to computers, deviations from standard operating procedures, and conflicts between
different IT systems. Time-motion analysis revealed that nurses’ activities took up the most time in the workflow and
contained a high frequency of shorter duration activities. Administrative assistants performed more activities near the
beginning and end of the workflow. Overall, clinical trial tasks had a greater frequency than clinic routines or other general
activities.
Conclusions: This paper describes a method for modeling clinical trial workflow in UML and standardizing these workflow
diagrams through a UML profile. In the increasingly global environment of clinical trials, the standardization of workflow
modeling is a necessary precursor to conducting a comparative analysis of international clinical trials workflows.
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Introduction
Clinical trials, though historically dominated by the UnitedStates
and a small subset of countries in North America and Western
Europe, are increasingly becoming a global activity with potential
implications on health care delivery around the world. Between
1990 and 1999, the number of countries conducting drug research
trackedbythe Foodand DrugAdministration[1]rosefrom28to79
[2], and by one recent estimate, 24 of the fastest 25 growing
countries in clinical trials are in emerging, non-traditional areas [3].
A study of industry sponsored phase 3 clinical trials in2007 revealed
that a majority of the sites were outside the United States [4].
Although the globalization of clinical trials brings many
potential benefits [3], a major challenge is faced regarding the
standardization of clinical trials conducted in different parts of the
world; the workflows of clinical trials, as well as the standards of
care in different countries may vary so much as to invalidate
individual trial results [4]. Ultimately, the relative performance of
clinical trials in emerging countries will depend on the internal
workflow of these research sites and the establishment of good
clinical trials practice guidelines. For example, a 2001 FDA report
notes that clinical trial ‘‘sponsors have raised concerns regarding
the capacity of the institutional review boards in some of the
emerging sites to adequately review research according to Good
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on Harmonization or FDA standards’’ [2]. Such variation in
clinical practice guidelines among emerging sites has ethical
implications, as well as implications on the trial workflow and
validity of results. Despite this, little research has been conducted
to analyze and/or compare the workflow of clinical trials, let alone
those operating across international boundaries [5]. This may, at
least partly, be due to the lack of standard computational
representation for these workflows, which would facilitate an
operational comparison of how clinical trials are being conducted
around the world. Additionally, a standard representation would
help create more homegeneous clinical trials, which would in turn
facilitate the implementation of better meta analyses.
Workflow modeling is an established technique of business
process re-engineering, and various studies have assessed its
potential in re-engineering organizational processes across various
quality measures or goals [6,7,8]. For example, workflow modeling
in business process re-engineering may be used to identify
inefficiencies or opportunities for cost reduction inherent in the
sequence of tasks [6]. Yet, the use of workflow modeling in the
clinical trials domain is less well established [5]. Few studies have
demonstrated the possible use of workflow modeling and analysis
towards re-engineering clinical trials [5,9,10], and research in this
area continues to suffer from the lack of standard representation
model. The variety in representation models may extend from the
use of different modeling languages to the use of different
representations or vocabularies within a single modeling language
[9,10]. For example, different studies may use different modeling
languages or symbols to represent the workflow, as well as different
semantic phrases to represent the same activity (i.e. ‘‘phlebotomy’’
vs. ‘‘drawing blood’’). Hence, the need for standardization applies
to both the use of a single modeling language, as well as a standard
representation to extend the modeling schema into the clinical
trials domain.
Clinical trial modeling in Unified Modeling Language (UML)
[11] provides a potential solution to some of these problems and
can serve as a standard format for workflow modeling. (Figure 1
provides an example of a workflow model in UML) UML allows
the detailed description of organizational processes in a so-called
Activity Diagram (AD), which can be annotated with data to
support process analysis [12,13]. (Figure 2 depicts a real world
example of an activity diagram representing a clinical process.)
Various studies have established the use of the UML activity
diagram in modeling of business processes [13], and some have
even demonstrated its use in the healthcare domain [14,15,16]. In
order to define a standard representation for UML models within
a domain like clinical trial, one can formulate a UML profile [17],
which enables independent developers to generate standardized
UML models at different sites [18,19]. The UML profile can be
loaded into a UML developing environment in order to apply a
standard set of data tags (attributes) to a workflow model; for
example, a UML profile defining a standard for colonoscopy
workflow might include a standard set of data attributes including
the type of endoscope being used, the names of physicians or
nurses, the type of sedation being used, and the duration of the
procedure. To this end, a UML profile for clinical trial workflow
might specify attributes which facilitate the gathering of data for a
time-motion study [20] to allow comparisons of efficiency in line
with the NIH roadmap goal of re-engineering clinical research
[21].
Given the rapid global expansion of clinical trials, the creation
of standard nomenclature for clinical trial workflow representation
can facilitate the analysis and comparison of workflows across
international sites. A standardized workflow representation might
also enable analyses of efficiency and cost, thereby allowing
researchers to shorten the length of a research study and expedite
the incorporation of sound research results into the healthcare
Figure 1. Example workflow model: Workflow begins at an Activity
Initial Node and ends at an Activity Final Node; ovals represent actions
in the workflow; diamond represents a decision node, where the
subsequent direction in the workflow is dependent on a decision.
doi:10.1371/journal.pone.0013893.g001
Figure 2. Activity Diagram for a Clinical Process. This activity
diagram represents the following activity: the patient is submitted to an
activity named ‘‘Test Procedure’’ that generates a result. One of results
redirects the flow of activity to an activity called ‘‘Refer back to GP’’ and
the activity is finished (filled circle with a border). Another result
redirects the flow to a ‘‘Treatment Preparation’’ activity. A black bar with
two flow leaving it means that the ‘‘Procedure X’’ and ‘‘Procedure Y’’ are
executing in parallel. A black bar with one flow leaving it redirects the
flow to the last activity called ‘‘Arrange next Appointment’’ and the
filled circle with a border finishs the activity. Source: http://citeseerx.ist.
psu.edu/viewdoc/download?doi=10.1.1.6.4217&rep=rep1&type=pdf.
doi:10.1371/journal.pone.0013893.g002
Trial Workflow Representation
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can aid in the process of establishing good clinical trial practice
guidelines across international sites participating in a given study.
The objective of this study was to design a UML profile to
extend the UML AD schema into the clinical trial domain,
thereby defining a standard representation for clinical trial
workflow diagrams modeled in UML at different sites. In
designing this profile, we paid particular attention to attributes
which may lend a description of time, distribution, efficiency, and,
ultimately, cost.
Methods
The study was approved by the local Institutional Review Board
at State University of Maringa, Brazil (Comite ˆ Permanente de
E ´tica em Pesquisa Envolvendo Seres Humanos – COPEP - da
Universidade Estadual de Maringa ´ - UEM). Verbal informed
consent was obtained as per guidance provided by the IRB, since
this is an observational study where no personal information was
recorded, thus anonymizing the study data. We evaluated the
workflow of clinical trials conducted at two private clinics, one
each in the cities of Maringa and Rio de Janeiro, Brazil. To
protect subject confidentiality as well as intellectual property of the
companies conducting the clinical trials, no clinical trial data was
accessed by workflow modelers. Subjects were anonymous to the
research team.
Study sample
The clinical trial sites were evaluated fora total of 53-clinic hours,
involving clinical trials related to rheumatology and oncology. At
both sites, a small research team was present with a single clinical
research coordinator (CRC) managing 5 to 6 clinical trials. During
clinic visits, we conducteda series ofethnographicobservations, also
performing interviews with the CRC, principal investigator, and
other staff direct or indirectly involved with clinical trial activities.
All notes and interviews were focused on workflow issues, their
variations across different circumstances, and subject’s perceptions
about their effectiveness and points of failure. Observations were
recordedinfieldnotes,which werelatertranscribed and analyzedto
create a list of workflow tasks.
Ethnographic study: interviews and time motions studies
Observation Categories. Observers [EC, AB] compiled an
overall list of activities from summarization of the original
ethnographic study and findings from previous studies, and then
subsequently documented study activities by choosing descriptors
from this list [10,22]. These activities were hierarchically classified
into major and minor activities based on consensus among the two
researchers collecting the data (EC, AB), thus facilitating data
collection.
Data Entry. Observers [EC, AB] recorded data in a laptop
using a MySQL database run locally from a Web browser
interface specially designed for this study. Beginning and end times
were recorded for each task. For each activity, observers recorded
an observation session ID, observer ID, CRC ID, and time stamp
measured to the nearest second. When a CRC was engaged in
multiple activities at the same time, such as ‘‘Asking the patient
how he is feeling’’ and ‘‘Recording in the chart,’’ the observer
ranked one profile as a primary activity and the other as a
secondary activity. If a CRC switched from one activity to another
in rapid succession, these activities were recorded in sequence.
Long transitional periods between separate activities were logged
as a separate activity under the descriptor ‘‘other,’’ while short
transitional periods associated, for example, with the time elapsed
between ‘‘taking the pulse’’ and ‘‘recording in the chart’’, were
logged as part of the second activity’s total duration [22].
UML modeling
As described in the introduction, Unified Modeling Language
(UML) is a computational language that can be used to represent
workflows of operational processes [11]. Accordingly, UML can be
used to model the workflow of businesses, procedures, or any
healthcare activity. In this study, we have used UML to model the
operational workflow of clinical trials.
All workflows in this study were modeled in UML 2.0 ADs via
the UML2 plugin [23] for Eclipse[24]. In our manuscript the term
‘‘UML’’ is often used in lieu of ‘‘UML2’’ to refer to diagrams
created via this UML2 plugin. Events in the workflow are
represented as oval-shaped structures called ‘‘Opaque Actions’’,
related to one another by transition arrows or ‘‘Control Flows’’.
‘‘Decision Nodes’’ are diamond-shaped elements that represent
forks in the workflow where the outgoing path depends on the
outcome of a decision (i.e. has the patient been consulted by a
doctor?). The overall workflow begins at an ‘‘Activity Initial Node’’
and ends at an ‘‘Activity Final Node.’’ All workflows confirm to
UML 2.0 standards as implemented in Eclipse.
In order to annotate the workflow, a UML profile (S 2) was
designed to incorporate all information from the ethnographic and
time-motion studies into the AD based on a use-case (fig 3) using
criteria defined in Table 1. The use-case describes a scenario
showing the functionality of the system from the view of the user
[11]. Meanwhile, the UML profile includes ‘‘stereotypes’’ or
grouped sets of attributes, which apply time, distribution, and cost
information to the workflow. The attributes were devised to
annotate the activity diagram (File S3) with the quantities of
information included in simulation software packages such as
AnyLogic [25] or Arena Simulation Software [26].
The profile can be applied to any AD created in Eclipse,
thereby standardizing the types of attributes applied to elements of
the workflow. For example, a hypothetical ‘‘time’’ stereotype in a
profile, containing duration and delay information, might be
applied to events in the workflow in order to annotate the diagram
with this data. Attributes in our profile which can be applied to
Opaque Actions include measures of duration, delay, fail rate,
rework rate, communication rate, and the units of measurement
used; attributes which can be applied to Decision Nodes include
measures of distribution, including the beta, continuous, discrete,
Erlang, exponential, gamma, Johnson, lognormal, normal,
Poisson, triangular, uniform, and Weibull distributions (see
Table 2 for details), in accordance with the statistical distribution
information included in Arena Simulation Software [27].
Results
Ethnographic notes on tasks
The ethnographic observations generated a list of tasks that are
listed and classified hierarchically by the following categories:
environment, clinical trial, clinical routines (File S1). Recurring
patterns observed across tasks that impaired workflow included (a)
CRCs in charge of tasks that required full commitment from them
(e.g., computerized tomography) resulted in long idle times where
the research coordinator could not accomplish other activities (b)
the transmission of notes from paper to electronic data capture
systems frequently resulted in activities that required extreme
attention and therefore were more prone to errors that could go
undetected (c) lack of use of standard operating procedures
frequently led to rework in workflow, since the first attempt to
execute an activity was accompanied by error or a missing step
Trial Workflow Representation
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record while coming to a subject evaluation and (d) lack of
integration across different information technology systems, such
as the electronic data capture system and the adverse event
reporting system being from different software packages.
Time and motion
Time & motion data for different hierarchical activities are
summarized through a mosaic chart where the width of the bar is
scaled to the proportion of the time required to complete the task,
comparing categories for physicians, nurses, and administrative
assistants (figure 4).
In Figure 4, white color indicates that the actors were busy
performing the task while red color indicates idle time or gaps
between tasks. The box width represents the proportion of tasks
performed by each of the actors amongst all the tasks. Box height
represents the time required to complete the task, and timestamps
along the vertical axis represent elapsed time in the workflow.
Physicians perform tasks consistently with shorter idle times, but
towards the end of the workflow they have relatively longer idle
time as compared with others. Physicians also have relatively a
smaller number of tasks compared to others, but they tend to
require a longer time for completion. At the beginning of the
workflow nurses have a smaller frequency of tasks and more idle
Figure 3. A global use case to specific actor use cases.
doi:10.1371/journal.pone.0013893.g003
Table 1. Criteria to build a use case for simulation.
Goal The goal of this use case is to drive the design of a UML profile to extend Activity Diagrams (AD). This extension will allow
researchers to upload UML ADs directly into computer simulation software as well as establish workflow comparison across
different clinical trials.
Summary The use case presents the creation of a UML AD with a description of its time as well as distribution components designed to be
compliant with the required information for a computer simulation.
Actors The UML modeler and the computer simulation specialist, although very often thesetwo actors will be represented by the same person.
Pre-conditions A researcher conducts an ethnographic study evaluating the workflow of a clinical trial site, resulting in a list of activities placed
in the most common sequential order. A time motion study is then conducted to assign average completion times for each of
the activities.
Triggers The case is initiated by the completion of the data collection stage of the ethnographic and time motion studies. These stages
provide the data that will populate the UML AD.
Basic course of events A UML activity diagram is created with the tasks in sequence as usually performed in a regular UML AD. These tasks are then
tagged with time data including multiple distribution parameters. Distribution parameters are also attached to different
random decision nodes. The UML AD is then uploaded to a computer simulation package used for discrete event simulation,
and then converted to a simulation model
Post-conditions The UML AD is converted into a computer simulation model, and any modifications made during the calculation of the
analytical solution to the model are automatically translated into the UML AD.
doi:10.1371/journal.pone.0013893.t001
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Beta (Beta, Alpha) Beta (b) and Alpha (a) specified as positive real numbers.
Continuous (P1, V1, …) P1 is a Pair of cumulative probabilities and V1 is an associated value.
Discrete(P1, V1, …) P1 is a Pair of cumulative probabilities and V1 is an associated value.
Erlang(ExpoMean, k) : ExpoMean are distributed exponential random variables and k is the number of exponential random variables.
Exponential(Mean) The mean (b) specified as a positive real number.
Gamma(Beta, Alpha) Shape parameter (a) and scale parameter (b) specified as positive real values.
Johnson(Gamma, Delta, Lambda, Xi) Gamma shape parameter (c), Delta shape parameter (d.0), Lambda scale parameter (l), and Xi location parameter (j).
Lognormal(LogMean, LogStd) Mean LogMean and standard deviation LogStd of the lognormal random variable. Both LogMean and LogStd must be
specified as strictly positive real numbers.
Normal(Mean, StdDev) The mean (m) specified as a real number and standard deviation (s) specified as a positive real number.
Poisson(Mean) The mean (l) specified as a positive real number.
Triangular(Min, Mode, Max) The minimum (a), mode (m), and maximum (b) values for the distribution specified as real numbers with a,m,b.
Uniform(Min, Max) The minimum (a) and maximum (b) values for the distribution specified as real numbers with a,b.
Weibull (Beta,Alpha) Shape parameter (a) and scale parameter (b) specified as positive real values.
*extracted from Arena User’s Guide, 2007.
doi:10.1371/journal.pone.0013893.t002
Figure 4. Summary of time & motion data for actors.
doi:10.1371/journal.pone.0013893.g004
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increases, resulting in very short idle times compared to others.
Nurses have a higher frequency of tasks as compared to others,
with time to completion being shorter and consistent throughout
the workflow. Finally, administrative assistants have fewer gaps
between their tasks at the start and the end of workflow, with but
has relatively longer idle time in the middle of the workflow. Their
task frequency is somewhere in the middle between nurses and
physicians, with the time required for task completion also being in
middle range. Figure 5, represents a mosaic chart comparing tasks
related to clinic routines, activities specific to the clinical trial, and
general tasks.
Tasks specific to the clinical trialpresenta few short gaps between
them at the start of the workflow, but throughout the workflow
period these tasks are performed in a clustered pattern. These tasks
have a greater frequency compared to tasks labeled as routine or
general, also having a shorter duration as compared to others.
Clinical routine tasks are initially performed at consistent intervals,
but idle times become greater towards the middle and end of the
workflow. Finally, tasks labeled as related to the environment had a
low frequency, but took long times for completion.
UML profile
We furnish the link for a UML profile designed in Eclipse to
incorporate additional characteristics required for workflow
modeling in clinical research. (File S2) It includes measures of
time and distribution, in accordance with the types of information
used in discrete event simulation models. The profile makes use of
‘‘stereotypes,’’ which are grouped sets of attributes; the attributes,
here, are technically ‘‘child’’ attributes, meaning that they
hierarchically belong to the ‘‘parent’’ stereotype. In the profile
we’ve created, the ‘‘Time-related attributes’’ stereotype includes
child property attributes of delay, fail rate, rework rate,
communication rate, duration, and units, which is defined under
an enumeration literal to take on a value of ‘‘seconds’’ or
‘‘minutes.’’ The ‘‘Time-related attributes’’ stereotype can be
applied to Opaque Actions representing events in an AD.
Figure 6 displays the annotation of the Opaque Action, ‘‘Check
the patient,’’ with the ‘‘Time-related attributes’’ stereotype.
Additional stereotypes were created for each of the distribution
types (beta, continuous, discrete, etc.) previously described, with
each distribution stereotype containing the appropriate child
attributes corresponding to the mathematical distribution (i.e. the
beta distribution stereotype contains child property attributes for
distribution parameters b and a). Each distribution stereotype can
be applied to decision nodes in an AD in order to annotate these
nodes with data according to a specific distribution. Although we
did not make use of any ‘‘generalizations’’ in our UML profile, the
‘‘generalization’’ feature allows for the specification of hierarchical
relationships between stereotypes, such that a more specific
Figure 5. Summarization of time & motion data for task activities.
doi:10.1371/journal.pone.0013893.g005
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child generalization created for a given sub-stereotype can refer to
a super-stereotype, from which the sub-stereotype will inherit all
attributes [18].
Discussion
To our knowledge, this is the first study evaluating the use of
UML activity diagrams to standardize the representation of
workflow in the clinical trial domain, thus extending previous
applications of UML in healthcare operations [14,15,16]. Our
main findings included ethnographic observations of patterns of
activities which caused workflow problems, and time-motion
analysis information regarding the relative duration of activities
performed by different actors in the workflow. Specifically,
workflow problems occurred with tasks requiring the full
commitment of clinical trial team, such that they could not
multi-task, the transfer of information from paper to electronic
systems, occasional deviations from standard operating protocols,
and idle time resulting from a lack of integration between different
IT systems. Our time-motion analysis also revealed the following
potential areas for intervention in the workflow to improve
efficiency: first, physician downtime appears to be greatest near
the beginning of the workflow and, accordingly, efficiency can be
increased by other actors performing all necessary tasks prior to
the physician entering the workflow, such that the physician can
perform tasks in an uninterrupted flow. Second, the administrative
assistants appear to experience the greatest downtime during the
middle of the workflow; accordingly, this would be an appropriate
time to take care of all environment or clinic routine tasks
unrelated to the clinical trial, in order to ensure the smooth
running of clinical trial activities. Third, the nurses appear to be
busy throughout the workflow, and so it appears that making sure
that their participation in the workflow runs efficiently at all times
may have the greatest overall impact on the efficiency of the
clinical trial workflow. Overall, clinical trial tasks were the most
prevalent tasks on the overall workflow than either clinic routines
or other general activities.
Though several studies [5,9,10] have examined workflow
modeling of clinical trials, they suffer from the lack of a standard
representation model. To the best of our knowledge, this is the first
study to use UML for modeling the operational workflow of
clinical trials. Furthermore, we have incorporated a time-motion
study into our workflow analysis via a UML profile. The UML
profile also serves to create a standard representation for clinical
trials workflow ADs, thereby facilitating comparison.
In the UML profile, stereotypes provide a convenient means for
creating a standard set of attributes for UML models. However,
the UML profile would be a more effective tool if given the ability
to restrict the semantics of UML diagrams. For example, if we
could have used our UML profile to limit the potential descriptors
of Opaque Actions in UML ADs to only those terms from a
standardized list of clinical trial activities, we could have effectively
promoted the use of a single, standardized vocabulary in the
creation of UML ADs modeling clinical trial workflow. With the
current profile, however, workflow models created at different sites
might conceivably use different descriptors for analogous or
equivalent activities, thus hindering comparative analysis of these
models.
Limitations of our study which could be subjects for future
research are as follows: first, we only evaluated a limited number of
sites in rheumatology and oncology - future studies should
examine more types of research groups with different workflows.
Second, though we have used a use case towards the goal of
directly importing workflow models into discrete event simulation
software, to our knowledge there is currently no import function of
this type available in any software. Future research should develop
interfaces with existing packages so that importing UML activity
Figure 6. Portion of the Activity Diagram created with the UML Profile, highlighting data annotation for ‘‘Check the patient’’.
doi:10.1371/journal.pone.0013893.g006
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though we dealt with standardizing the data annotation for UML
workflow models of clinical trials, we did not address the
standardization of terminologies or vocabularies used in these
workflow models. To reiterate, the UML profile would greatly
benefit from the ability to restrict the semantics of UML diagrams.
Further, we also did not generate an international comparison
of clinical trials workflows using our profile as this was beyond the
scope of our study, and thus we have not explicitly demonstrated
the reengineering of a clinical research group based on
information gathered from our UML workflow analysis. Future
works should utilize the UML profile towards comparing work-
flows of clinical research groups in different countries and
demonstrate the use of this analysis towards actually reengineering
the workflow of a clinical research group. This reengineering
process might then be evaluated for its effectiveness in improving
clinical trials workflow across various quality measures or goals.
We should also note that while this paper makes progress
towards developing a standardized computational representation
for clinical trial workflow, much work remains to be done in order
to establish a true standard representation. Our work is limited to
the particular clinical trials we have studied, and many more
should be examined before a true standard can be developed.
Future research might expand this project through examining
more types of clinical trials and developing a standard terminology
for the processes associated with these clinical trials.
In conclusion, this paper describes a method for modeling
clinical trials workflows in UML Activity Diagrams and standard-
izing these workflow diagrams through a UML profile. The model
we’ve created demonstrates the process of building a standard
clinical trial model in UML and annotating it with time-motion
data. In the increasingly global environment of clinical trials, the
standardization of workflow modeling is a necessary precursor to
conducting a comparative analysis of international clinical trials
workflows. Future research might use this standardized workflow
representation to generate workflow diagrams of clinical trials in
emerging countries and compare these to workflow diagrams of
clinical trials in the US.
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